Latest ATAGI advice on COVID-19 vaccinations
A summary of COVID-19 vaccine clinical resources is available on the Australian Government Department of Health and Aged Care website.
For public health alerts and advisories relating to COVID-19 and other threats to the health and wellbeing of Canberrans, see the ACT Chief Health Officer alerts.
Advice on COVID-19 vaccination
For the latest Australian Technical Advisory Group on Immunisation (ATAGI) advice on COVID-19 vaccination see:
- Australian Immunisation Handbook - COVID-19 Recommendations
- ATAGI Statement on the Administration of COVID-19 Vaccines in 2024
See the Australian Government Department of Health and Aged Care- Advice for COVID-19 vaccine providers and administrators for other information, including vaccine allocations, storage and handling, managing bookings, charging for consultations, and resources to give patients.
Reporting an adverse event following immunisation (AEFI)
An adverse event following immunisation (AEFI) is described in the Australian Immunisation Handbook as any negative reaction that follows vaccination. It does not necessarily have a causal relationship with the vaccine.
The adverse event may be any:
- unfavourable or unintended sign
- unfavourable or unintended symptom
- disease
- abnormal laboratory finding
These events may be caused by the vaccine(s) or may occur by chance (that is, the event would have occurred regardless of vaccination).
An AEFI is a notifiable condition under the ACT Public Health Act (1997).
All uncommon, unexpected or serious AEFI, or any event considered to be significant following immunisation, must be notified by medical practitioners or other health professionals to ACT Health by either:
- phoning the ACT Health Immunisation Section on (02) 5124 9800 (Monday-Friday, 8.30am to 4.30pm); or
- completing the online Immunisation Adverse Event (vaccination reaction) Reporting Form
For urgent advice after hours, contact the Immunisation Section on (02) 5124 9800 and follow the prompts.
All notifications of AEFI received by ACT Health will be reviewed and also reported to the Therapeutic Goods Administration (TGA).
Information on reporting adverse events following immunisation is also available on the ACT Health website.
Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines
COVID-19 vaccination guidance on myocarditis and pericarditis after mRNA has been developed jointly by the Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ).
